Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Indivior Pharmaceuticals has reported Short term Debt over the past 5 years, most recently at $29.0 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 61.11% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $29.0 million, up 61.11%, while the annual FY2025 figure was $29.0 million, 61.11% up from the prior year.
  • Short term Debt for Q4 2025 was $29.0 million at Indivior Pharmaceuticals, up from $18.0 million in the prior quarter.
  • Over five years, Short term Debt peaked at $29.0 million in Q4 2025 and troughed at $3.0 million in Q4 2021.
  • A 5-year average of $13.8 million and a median of $18.0 million in 2024 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: changed 0.0% in 2022 and later soared 500.0% in 2024.
  • Year by year, Short term Debt stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then soared by 500.0% to $18.0 million in 2024, then surged by 61.11% to $29.0 million in 2025.
  • Business Quant data shows Short term Debt for INDV at $29.0 million in Q4 2025, $18.0 million in Q3 2025, and $18.0 million in Q2 2025.